Home PharmTech DSM-Firmenich CBD Product Shows Promise in OSD Forms, Study Says

DSM-Firmenich CBD Product Shows Promise in OSD Forms, Study Says

by Newsroom


TOP NEWS on grunge world map | Image Credit: © Sean K – stock.adobe.com

Data from a clinical study have shown that CBtru, a cannabidiol (CBD) drug product intermediate from DSM-Firmenich, is absorbed into the bloodstream at a similar level to Jazz Pharmaceuticals’ Epidiolex, the first and currently only commercially approved CBD drug product on the market (1). According to DSM-Firmenich (stylized as dsm-firmenich), it is the first time a solid CBD formulation has demonstrated absorption comparable to a liquid/oil-based reference product.

DSM-Firmenich, which has headquarters in The Netherlands and Switzerland, said in a Feb. 20, 2025 press release…



Source link

You may also like

About Us

Pharma Newswire™ aggregates, publishes and distributes news in the Pharmaceutical Industry. In association with EmailWire, Pharma Newswire™ provides press release distribution services in the pharmaceutical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. To send a press release, contact us through the following messaging apps:

Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC